Real world use of oral treatments in interstitial cystitis/bladder pain syndrome in the UK: Outcome of a cross sectional study
Real world use of oral treatments in interstitial cystitis/bladder pain syndrome in the UK: Outcome of a cross sectional study
Background: To describe the oral treatments people living with interstitial cystitis/bladder pain syndrome (IC/BPS) are using to treat their urologic condition in the UK. Method: A questionnaire hyperlink encompassing current and previous medications taken for IC/BPS with other sociodemographic and diagnostic indices was available to the Bladder Health UK website. Interested and fully consented individuals accessed and completed the survey. Results: A total of 601 accessed the questionnaire of whom 173 participants responded (response rate: 28.7%) with a mean ± SD O'Leary/Sant scores of 20.12 ± 9.38. A sample size of 171 was estimated to be used in the survey. A fifth of the participants were not on any treatment at all. Amitriptyline was the most prevalent medication in use both alone and in combination. A shift in the use of unapproved (for IC/BPS) antidepressant, smooth muscle relaxant, opioids, gabapentenoids, and antibiotics was observed in the sample. There were no significant differences between the mean (SD) O'Leary/Sant scores of cohorts currently taking oral medications and those not taking it. More than two-thirds of the participants had been diagnosed with the disease more than 5 years. Just under a half (47.4%) of participants reported a history of allergy. Conclusion: Our study provides contemporary evidence that the treatments used for managing IC/BPS encompass a broad range of medications both recommended and not recommended by current guidelines. The latter suggests patients are willing to try novel treatments when more conventional ones are ineffective.
amitriptyline, comorbidity, interstitial cystitis/pain bladder syndrome, oral treatments
416-422
Garba, Kamaluddeen
44ade4a2-0f98-4e98-885b-4a7c38c7f88c
Avery, Miriam
a678263d-a1de-486a-8553-e84c831f9149
Yusuh, Muhammadbukhoree
7c176a00-3c8c-4be8-a747-3edacd4710a2
Abdelwahab, Omar
b0107277-5b5b-46c0-942f-33f9c800beae
Harris, Scott
19ea097b-df15-4f0f-be19-8ac42c190028
Birch, Brian R.
8a94cd36-d429-4ab4-82a6-a376b4d4e10f
Lwaleed, Bashir A.
e7c59131-82ad-4a14-a227-7370e91e3f21
January 2022
Garba, Kamaluddeen
44ade4a2-0f98-4e98-885b-4a7c38c7f88c
Avery, Miriam
a678263d-a1de-486a-8553-e84c831f9149
Yusuh, Muhammadbukhoree
7c176a00-3c8c-4be8-a747-3edacd4710a2
Abdelwahab, Omar
b0107277-5b5b-46c0-942f-33f9c800beae
Harris, Scott
19ea097b-df15-4f0f-be19-8ac42c190028
Birch, Brian R.
8a94cd36-d429-4ab4-82a6-a376b4d4e10f
Lwaleed, Bashir A.
e7c59131-82ad-4a14-a227-7370e91e3f21
Garba, Kamaluddeen, Avery, Miriam, Yusuh, Muhammadbukhoree, Abdelwahab, Omar, Harris, Scott, Birch, Brian R. and Lwaleed, Bashir A.
(2022)
Real world use of oral treatments in interstitial cystitis/bladder pain syndrome in the UK: Outcome of a cross sectional study.
Neurourology and Urodynamics, 41 (1), .
(doi:10.1002/nau.24840).
Abstract
Background: To describe the oral treatments people living with interstitial cystitis/bladder pain syndrome (IC/BPS) are using to treat their urologic condition in the UK. Method: A questionnaire hyperlink encompassing current and previous medications taken for IC/BPS with other sociodemographic and diagnostic indices was available to the Bladder Health UK website. Interested and fully consented individuals accessed and completed the survey. Results: A total of 601 accessed the questionnaire of whom 173 participants responded (response rate: 28.7%) with a mean ± SD O'Leary/Sant scores of 20.12 ± 9.38. A sample size of 171 was estimated to be used in the survey. A fifth of the participants were not on any treatment at all. Amitriptyline was the most prevalent medication in use both alone and in combination. A shift in the use of unapproved (for IC/BPS) antidepressant, smooth muscle relaxant, opioids, gabapentenoids, and antibiotics was observed in the sample. There were no significant differences between the mean (SD) O'Leary/Sant scores of cohorts currently taking oral medications and those not taking it. More than two-thirds of the participants had been diagnosed with the disease more than 5 years. Just under a half (47.4%) of participants reported a history of allergy. Conclusion: Our study provides contemporary evidence that the treatments used for managing IC/BPS encompass a broad range of medications both recommended and not recommended by current guidelines. The latter suggests patients are willing to try novel treatments when more conventional ones are ineffective.
Text
Real World Use of Oral Treatments...
- Accepted Manuscript
More information
Accepted/In Press date: 12 November 2021
e-pub ahead of print date: 29 November 2021
Published date: January 2022
Additional Information:
Funding Information:
The study was partly supported by the Petroleum Technology Development Fund (PTDF), Nigeria. We are grateful for the Bladder Health UK for supporting the study.
Funding Information:
The study was partly supported by the Petroleum Technology Development Fund (PTDF), Nigeria. We are grateful for the Bladder Health UK for supporting the study.
Publisher Copyright:
© 2021 Wiley Periodicals LLC
Keywords:
amitriptyline, comorbidity, interstitial cystitis/pain bladder syndrome, oral treatments
Identifiers
Local EPrints ID: 452945
URI: http://eprints.soton.ac.uk/id/eprint/452945
ISSN: 0733-2467
PURE UUID: 365c78c6-3ea5-4d8b-896a-184a428e794f
Catalogue record
Date deposited: 07 Jan 2022 11:18
Last modified: 06 Aug 2024 01:39
Export record
Altmetrics
Contributors
Author:
Kamaluddeen Garba
Author:
Miriam Avery
Author:
Muhammadbukhoree Yusuh
Author:
Omar Abdelwahab
Author:
Brian R. Birch
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
